Epilepsy – Unmet Need – Unmet Need – Epilepsy: Generalized-Onset Seizures (US/EU)
Generalized onset seizures (GOS) originate simultaneously in both hemispheres of the brain and account for nearly 40% of all epilepsy cases. Current management relies primarily on widely used therapies such as Keppra (levetiracetam), Lamictal (lamotrigine), and Vimpat (lacosamide), which form the backbone of treatment across lines of therapy. Despite multiple available options, achieving consistent seizure control with an acceptable safety profile remains challenging. The extensive availability of generics has further contributed to a crowded and competitive landscape, with limited differentiation among existing therapies. Consequently, there is a significant unmet need for treatment approaches that deliver improved effectiveness, enhanced safety, and more individualized management. This report provides stakeholders with a focused and actionable understanding of the market dynamics shaping current unmet needs in GOS.
Questions answered
- How do existing therapies perform across the attributes that most influence prescribing, and which differentiation gaps present the greatest opportunities for competitive advantage?
- What factors most strongly influence treatment selection in this indication, and how do these priorities vary by region?
- Which unmet needs remain critical in GOS, and what hidden or underserved opportunity areas could support future differentiation and innovation?
- Based on a conjoint analysis and TPP simulation, what trade-offs between clinical attributes and price are neurologists willing to make for a hypothetical new GOS therapy?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 63 U.S. and 31 European neurologists fielded in December 2025
Key drugs: Keppra, Lamictal, Depakene, Fycompa, Vimpat, and others
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
Key analyses
- Importance of clinical and nonclinical product attributes to physicians
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Remaining drug development opportunities
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
